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The H3K27 histone methyltransferase, Ezh2 (enhancer of
zeste 2), is a Polycomb group protein that plays important roles
in many biological processes including cellular differentiation,
stem cell biology, and cancer development. Up-regulation of
Ezh2 is observed in various human cancers consistent with its
role in cell proliferation. Thus, understanding the regulation of
Ezh2 may reveal how it contributes to the cellular proliferation
process.Here, we demonstrate that Ezh2 can be regulated by the
cyclin-dependent kinase, CDK1, which phosphorylates Ezh2 at
threonines 345 and 487. Consistent with the cell cycle phase
during which CDK1 exhibits peak activity, Ezh2 phosphoryla-
tion is enriched in cells arrested inmitosis when compared with
S-phase. Phosphorylation of Thr-345 and Thr-487 promotes
Ezh2 ubiquitination and subsequent degradation by the protea-
some. Furthermore, expression of T345A/T487A confers a pro-
liferative disadvantage when compared with cells expressing
wild-type Ezh2, which suggests that phosphorylation of Ezh2 is
important for cell proliferation.Collectively, these results estab-
lish a novel function for CDK1-mediated Ezh2 phosphorylation
and provide a mechanism by which Ezh2 protein levels can be
regulated in cells.
Ezh22 (enhancer of zeste 2) is a member of the Polycomb
group (PcG) proteins, which are evolutionarily conserved from
Drosophila to mammals. Originally discovered in Drosophila,
PcG proteins play an important role in regulating expression of
HOX genes, which encode a set of transcription factors that
specify the anterior-posterior axis and segment identity (1–3).
As the catalytic subunit of Polycomb repressive complex 2
(PRC2), Ezh2 has the capacity to trimethylate lysine 27 of his-
tone H3 (H3K27me3) but requires Suz12 (suppressor of zeste)
and Eed (embryonic ectoderm development) for its enzymatic
function (4–8). Biologically, Ezh2 plays an important role in
epigenetic gene silencing and has been linked to diverse pro-
cesses including developmental patterning, X-inactivation, and
stem cell biology (9–11).
In addition to the functions mentioned above, a number of
studies have also implicated a role for Ezh2 in cell proliferation
and oncogenesis. For example, ectopic expression of Ezh2 con-
fers a proliferative advantage in primary cells (12). In addition,
Ezh2 is often aberrantly overexpressed in a variety of human
cancers when compared with normal tissues (13, 14). Consis-
tently, RNAi-mediated knockdown of Ezh2 compromises cell
proliferation (12, 14, 15).
Although PcG proteins are best known for maintaining the
repression of HOX genes during development, they also play a
critical role in silencing the CDKN2A (cyclin-dependent kinase
inhibitor 2A) locus, which encodes for the tumor suppressor
genes p16INK4A and p14ARF. In young proliferating cells, eva-
sion of senescence requires repression of CDKN2A, which is
mediated by Ezh2 and H3K27 trimethylation (16–18). Consis-
tent with this, Ezh2 expression is high in proliferating cells but
is down-regulated in stressed and senescent cells. Hence, it is
believed that overexpression of Ezh2 contributes to oncogene-
sis by inappropriately silencing tumor suppressor genes.
The above observations illustrate the importance of main-
taining proper Ezh2 levels for normal function of cells. How-
ever, limited studies have been performed with respect to how
cellular levels of Ezh2 are controlled. Transcription of the Ezh2
gene is regulated by the pRB-E2F pathway and peaks at the G1-
to S-phase transition (12). Degradation of Ezh2 mRNA can be
targeted by miR-101, whose expression decreases during can-
cer progression (15), which provides one explanation as to how
Ezh2 levels are deregulated in cancer. Thus, it appears that Ezh2
is regulated at the transcriptional and post-transcriptional
level.
Here, we report that Ezh2 phosphorylation can occur at two
highly conserved residues, threonines 345 and 487. This mod-
ification can be mediated by the cyclin-dependent kinase,
CDK1. Consistent with the notion that CDK1 is a mitotic
kinase, enrichment of phospho-Ezh2 is observed in cells
arrested at mitosis when compared with S-phase. Interestingly,
the half-life of phospho-Ezh2 is shorter when compared with
total Ezh2, and phospho-Ezh2 is subject to ubiquitination.
Expression of the phospho-deficient mutant T345A/T487A
results in a proliferative disadvantage when compared with
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cells expressing wild-type Ezh2. Collectively, these studies pro-
vide the first evidence linking Ezh2 protein levels to cell cycle-
regulated Ezh2 phosphorylation.
EXPERIMENTAL PROCEDURES
Cell Culture, Transfections, and Drug Treatments—
HEK293T, HeLa, U2OS, and NIH3T3 cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal bovine serum and penicillin/streptomycin. PC3
cells were cultured inDMEM/F12 (1:1) supplementedwith 10%
fetal bovine serum and penicillin/streptomycin. Transfections
were performed using Lipofectamine 2000 (Invitrogen catalog
number 11668-019) or FuGENE 6 (Roche Applied Science cat-
alog number 11814443001). Roscovitine was purchased from
Cell Signaling Technology (catalog number 9805) and used at a
final concentration of 50M. CGP74514A (Sigma catalog num-
ber C3353) was used at a final concentration of 2M. Cyclohex-
imide (Sigma catalog number C4859) was used at a final con-
centration of 100 g/ml.
Antibodies—The following antibodies were used in this
study: FLAG M2 mouse monoclonal (Sigma catalog number
F3165), mouse phospho-serine (Chemicon catalog number
AB1603), mouse phospho-threonine (Cell Signaling catalog
number 9386), mouse phospho-tyrosine 4G10 (gift from
Weiguo Zhang, Duke University), rabbit Ezh2 (Cell Signaling
catalog number 4905), rabbit SLBP (gift fromWilliamMarzluff,
University of North Carolina), mouse cyclin B1 (Santa Cruz
Biotechnology), mouse -tubulin (Sigma catalog number
T6199), lamin B (Santa Cruz Biotechnology catalog number
sc-6217), mouse GST (Santa Cruz Biotechnology catalog num-
ber sc-138), rabbit H3K27me3 (Millipore catalog number
07-449), rabbit H3 (Abcam catalog number ab1791-100), and
rabbit Suz12 (as described in Ref. 5). Antibodies against Thr(P)-
345 and Thr(P)-487 were produced by injecting keyhole limpet
hemocyanin-conjugated phosphorylated peptides into rabbits
using a standard protocol outlined by Pocono Rabbit Farm and
Laboratory (Canadensis, PA). The sequences of the peptides
used are as follows: Thr(P)-345 (CTAERIK(pT)PPKRPG-NH2)
and Thr(P)-487 (Ac-CPTEDVD(pT)PPRKK) (where pT indi-
cates Thr(P)).
Lentiviral Constructs—The lentiviral system has been
described previously (19). FLAG-tagged wild-type Ezh2,
T345A/T487A, and T345E/T487E were cloned into the vector
pTYF under the control of the EF1 promoter. For knockdown
experiments, shRNAs targeting human EZH2 as well as a con-
trol shRNAswere cloned into pTYF under the control of theU6
promoter. The targeting sequences are as follows: control
knockdown (5-GTTCAGATGTGCGGCGAGT-3) and
EZH2 knockdown (5-GCTGCCTTAGCTTCAGGAA-3).
Cell Extract Preparation and Immunoprecipitation—Cell
pellets were resuspendedwith RIPA lysis buffer consisting of 50
mM Tris (pH 7.4), 1% Nonidet P-40, and 150 mM NaCl supple-
mented with protease and phosphatase inhibitors (Roche
Applied Science Complete protease inhibitor catalog number
11697498001 and Roche Applied Science PhosSTOP catalog
number 04906837001). Lysates were incubated on ice for 45
min and subjected to centrifugation at 17,000  g for 15 min at
4 °C. The resulting supernatant was transferred to a new tube,
and the protein concentration of the lysate was determined by
Bradford assay (Bio-Rad Protein Assay catalog number 500-
0006). For FLAG immunoprecipitations, 30 l of -FLAG M2
affinity gel (Sigma catalog number A2220) was added to the
lysates and rotated at 4 °C overnight. Bound proteins were
washed three times with RIPA lysis buffer prior to the addition
of 2 SDS loading buffer. Boundproteinswere then resolved by
SDS-PAGE.
Metabolic Labeling—Phosphate-free medium was prepared
using DMEM without sodium phosphate (Invitrogen catalog
number 11971) supplemented with 10% FBS, which was dia-
lyzed overnight against Tris-buffered saline (50 mM Tris, pH
7.4, 150 mMNaCl) using 3500 molecular weight cut-off dialysis
tubing. TransfectedHEK293T cells were first washed oncewith
phosphate-free medium and then labeled with phosphate-free
medium containing 1 mCi of [-32P]ATP (PerkinElmer Life
Sciences catalog number NET155001MC) for 3.5 h at 37 °C.
Cells were harvested and subjected to RIPA lysis and FLAG
immunoprecipitation as described above.
Subcellular Fractionation—For HeLa cytosolic extracts,
nuclear extracts, and nuclear pellet, previously prepared frac-
tionswere used (4, 20). For subcellular fractionation ofNIH3T3
cells, the cell pellet was resuspended in lysis buffer A (10 mM
Tris, pH 8.0, 140 mM NaCl, 1.5 mM MgCl2, and 0.5% Nonidet
P-40) supplemented with protease and phosphatase inhibitors
followed by incubation on ice for 5 min. Nuclei were centri-
fuged at 1000 g for 3min at 4 °C. The supernatant containing
the cytosolic fraction was transferred. The pellet was resus-
pended in the same volume of RIPA lysis buffer containing pro-
tease and phosphatase inhibitors. After incubation on ice for 30
min, the insoluble material was centrifuged at 17,000 g for 15
min at 4 °C. The supernatant containing the nuclear extractwas
recovered.
In Vitro Phosphatase and Kinase Assays—Immunoprecipi-
tated proteins were incubated with 1 l of PP1 (New England
Biolabs catalog number P0754) or -PPase (New England Bio-
labs catalog number P0753) in the supplied reaction buffer for
1 h at 30 °C. Recombinant GST-Ezh2 was incubated with
CDK1-cyclin B (New England Biolabs catalog number P6020)
in the presence of 1 mM cold ATP for 30 min at 30 °C. The
reaction was terminated by the addition of 5 SDS loading
buffer. Reaction products were analyzed by Western blot
analysis.
Cell Cycle Synchronization—HeLa cells arrested at S-phase
were obtained through double thymidine block, whereas
M-phase arrested cells were collected after thymidine-nocoda-
zole block. In short, cells were first treatedwith 1mM thymidine
for 18 h. Cells were washed two times with PBS and released for
4 h (M-phase) or 6 h (S-phase) prior to a second block with 1
mM thymidine (S-phase) or 0.1 g/ml nocodazole (M-phase)
for 16 h.
In VivoUbiquitination Assay—Cell pellets were resuspended
in preboiled SDS-lysis buffer (50 mM Tris, pH 7.5, 0.5 mM
EDTA, 1% SDS, 1mMDTT) and further boiled for an additional
10 min. Lysates were clarified by centrifugation at 17,000  g
for 10 min at 4 °C. The supernatant was transferred to a new
tube, and protein concentration was measured by Lowry Assay
(Bio-Rad DC protein assay catalog number 500-0112). For
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immunoprecipitations, lysates were first diluted 10-fold with
RIPA lysis buffer and then incubated with 20 l of -FLAGM2
affinity gel (Sigma catalog number A2220) overnight at 4 °C.
Bound proteins were washed three times with RIPA lysis buffer
and eluted with 2 SDS loading buffer.
Cell Proliferation Assay—Cell proliferation was monitored
by absorbance using theMTS assay (CellTiter 96AQueousOne
Solution cell proliferation assay, Promega catalog number
G3582). Approximately 5000 cells/well were seeded in tripli-
cate in a 96-well plate. At the indicated times, 20 l of the
reagent was added to the cells and incubated at 37 °C for 1.5 h.
Absorbance at 490 nm was measured in a microplate reader.
Following background subtraction, the number of cells was
back-calculated using an established standard curve. The num-
ber of cells at day 0 was set to 1. Additional experimental pro-
cedures can be found in supplemental methods.
RESULTS
Serine 21 Is Not a Major Ezh2 Phosphorylation Site—Ezh2
has previously been reported to be a phospho-protein (21). To
confirm this finding, HEK293T cells expressing FLAG-tagged
Ezh2 were metabolically labeled with [-32P]ATP. Following
FLAG immunoprecipitation, bound proteins were treated with
or without protein phosphatase 1 (PP1) or -protein phospha-
tase (-PPase) before being resolved by SDS-PAGE. Results
shown in Fig. 1A confirm that Ezh2 is indeed phosphorylated
and that treatment with either PP1 or -PPase diminishes the
signal (lanes 2–4). Western blot analysis using FLAG antibod-
ies verifies that FLAG-tagged Ezh2 is present at similar
amounts in all three lanes. Because Ser-21 of Ezh2 was previ-
ously reported to be an Akt phosphorylation site (21), we asked
whether additional phosphorylation sites other than Ser-21
exist. To this end, a parallel metabolic labeling experiment
expressing amutant FLAG-tagged Ezh2 (S21A)was performed.
Results shown in Fig. 1A demonstrated that the S21A mutant
Ezh2 can also be phosphorylated, roughly to the same degree as
wild-type Ezh2 (lanes 5–7), indicating that Ezh2 contains other
phosphorylation sites, in addition to Ser-21.
Ezh2 Is Threonine-phosphorylated—To narrow down which
amino acids of Ezh2 can be phosphorylated, we took advantage
of antibodies recognizing phospho-serine, phospho-threonine,
and phospho-tyrosine. HEK293T cells were transfected with
FLAG-tagged Ezh2, and after immunoprecipitation using
FLAG antibodies, bound proteins were treated with or without
-PPase, which is capable of removing the phospho-group from
all three residues. Western blot analysis using the residue-spe-
cific phospho-antibodies revealed that Ezh2 is threonine-phos-
phorylated as -PPase treatment greatly diminished the signal
(Fig. 1B, second panel). In contrast, similar treatment did not
result in significant changes in Ser or Tyr phosphorylation lev-
els, although these results cannot rule out the possibility that
Ezh2 is subjected to Ser or Tyr phosphorylation as detection of
thesemodifications depends on both the quality of the antibody
as well as the abundance of the modification. Nevertheless, the
above results demonstrate that Ezh2 is subject to threonine
phosphorylation.
Ezh2 Is Phosphorylated at Both Thr-345 and Thr-487 in Vivo—
To determine which threonines of Ezh2 may be phosphor-
ylated, we utilized a combination of phosphorylation site
prediction programs (MotifScan and NetPhos) and pub-
lished phospho-proteomic data. With this approach, two
putative phosphorylation sites were of great interest, thre-
onines 345 and 487. Under the highest stringency, both pro-
grams predicted these two sites, and in the case of MotifScan,
they were the only sites that were scored within the top 1%.
Previous phospho-proteomic studies also identified Thr-345
and Thr-487 of Ezh2 to be phosphorylated (22, 23). These res-
idues are highly conserved in humans, mice, and zebrafish,
whereas Thr-487 is also conserved in flies (Fig. 2A).
To gain insight into the function of their phosphorylation,we
generated antibodies that specifically recognize these phos-
phorylation sites. After two-step affinity purification, dot blot
analysis confirmed that the antibodies are specific for peptides
containing the phosphorylated threonine residues (Fig. 2B).
Furthermore, both phospho-specific antibodies recognize
exogenously expressed wild-type Ezh2 that was immunopre-
cipitated, but not when the phosphorylation site was mutated
to an alanine (Fig. 2C).
To determine whether endogenous Thr(P)-345 and Thr(P)-
487 is present in cells, we performed Western blot analysis
using subcellular protein extracts fromHeLa andNIH3T3 cells.
As a control, we also included recombinant PRC2 complex
purified from Sf9 cells. Results shown in Fig. 2D demonstrate
that the Thr(P)-345 antibody recognized a band corresponding
to the size of recombinant Ezh2 as well as a slower migrating
band in both the nuclear extract and the nuclear pellet fractions
derived from HeLa cells as well as nuclear extracts from
NIH3T3 cells (Fig. 2D, first panel). On the other hand,Western
blot analysis with the Thr(P)-487 antibody detected one band
corresponding to the size of Ezh2 in the NIH3T3 nuclear
FIGURE 1. Ezh2 is threonine-phosphorylated. A, Ezh2 is phosphorylated in
sites other than Ser-21. HEK293T cells exogenously expressing FLAG-tagged
wild-type Ezh2 or S21A were radiolabeled with [-32P]ATP. Following immu-
noprecipitation using FLAG antibodies, bound proteins were treated with no
phosphatase, with PP1, or with -PPase. Autoradiography (Autorad) confirms
that both wild-type and S21A mutant Ezh2 are phosphorylated and that the
signal diminishes upon phosphatase treatment. Bottom panel verifies that
equal amounts FLAG-Ezh2 were used in the assay. Ctrl, control. B, Ezh2 is
threonine-phosphorylated. FLAG-Ezh2 was transfected into HEK293T cells
and immunoprecipitated using FLAG antibodies. Bound proteins were
treated with or without -PPase and subjected to Western blot analysis using
antibodies specific for phospho-serine (-pSer), phospho-threonine (-pThr),
and phospho-tyrosine (-pTyr).
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extract and the HeLa nuclear pellet (Fig. 2D, second panel).
When more protein extract was loaded, Thr(P)-487 was also
detected inHeLanuclear extracts (data not shown). It should be
noted that the Thr(P)-487 antibody was raised against the
mouse sequence that contains one nonconserved amino acid
when comparedwith the human sequence (Fig. 2A), whichmay
account, in part, for the decreased sensitivity toward Thr(P)-
487 in HeLa nuclear extracts when compared with NIH3T3
nuclear extracts. Nevertheless, the results demonstrate that the
phospho-Ezh2 antibodies can detect endogenous bands corre-
sponding to the size of recombinant Ezh2.
To further confirm that the detected bands are indeed phos-
phorylated Ezh2, HeLa cells stably expressing shRNAs target-
ing Ezh2were generated by lentiviral infection. Following puro-
mycin selection, we performed quantitative RT-PCR, which
demonstrated roughly 80% knockdown at themRNA level (Fig.
2E, top panel). Consistent with this observation, a dramatic
decrease in Ezh2 protein levels was also detected (Fig. 2E, bot-
tom panel). Importantly, Western blot analysis using both
phospho-Ezh2 antibodies confirmed that the bands corre-
sponding to the size of Ezh2 diminished upon Ezh2 knockdown
(Fig. 2E, bottom panel). Furthermore, the slower migrating
band observed in the Thr(P)-345 Western blot remained
unchanged upon Ezh2 knockdown, indicating that this is a
cross-reacting band, whereas the faster migrating band corre-
sponds to Thr(P)-345 Ezh2 as this band decreases upon Ezh2
knockdown. Collectively, the above results demonstrate the
specificity of our phospho-Ezh2 antibodies as well as the pres-
ence of phosphorylated Ezh2 (Thr(P)-345 and Thr(P)-487) in
the cells tested.
When compared with control knockdown cells, Ezh2 knock-
down HeLa cells appeared larger and rounder (supplemental
Fig. S1A) and proliferated significantly more slowly (supple-
mental Fig. S1B). Flow cytometry analysis of DNA content indi-
cated that there was a higher percentage of cells in G2/M-phase
in the Ezh2 knockdown cells when compared with the control
(supplemental Fig. S1C), consistent with previous studies in
prostate cancer cells (14). Thus, these data confirm the finding
that Ezh2 plays a role in cell proliferation and extend this obser-
vation to HeLa cells.
CDK1 Phosphorylates Ezh2 at both Thr-345 and Thr-487 in
Vitro and in Vivo—Close inspection of the amino acid residues
surrounding both Thr-345 and Thr-487 revealed the presence
of a CDK1 consensus sequence ((S/T)PX(R/K)) (Fig. 2A). As a
FIGURE 2. Ezh2 is phosphorylated at threonines 345 and 487. A, threonines 345 and 487 are conserved across species. Human, mouse, zebrafish, and fly Ezh2
were aligned using MultAlin. Relevant regions are shown. Threonines 345 and 487 are underlined, whereas conserved amino acids are highlighted in bold.
B, specificity test of the phospho-Ezh2 antibodies. Dot blot analysis was performed using 2-fold dilutions of the unmodified (Unmod.) and phosphorylated
(Phos.) peptides corresponding to amino acids surrounding Thr-345 or Thr-487. C, exogenously expressed Ezh2 is phosphorylated at Thr-345 (pT345) and
Thr-487 (pT487). HEK293T cells were transfected with empty vector (Ctrl) or FLAG-tagged wild-type (F-WT), T345A (F-T345A), or T487A mutant Ezh2 (F-T487A).
Following FLAG immunoprecipitation, bound proteins were analyzed by Western blot analysis using the indicated antibodies. D, endogenous Ezh2 is phos-
phorylated at Thr-345 and Thr-487. Western blot analysis of NIH3T3 and HeLa cell extracts using the phospho-Ezh2 antibodies was performed. For NIH3T3
extracts, 100 g of nuclear extract (NE) and the equivalent volume of cytoplasmic extract (CYT) were loaded. For HeLa extracts, 100 g of each fraction was
loaded. Recombinant PRC2 complex was used as a positive control. Subcellular fractionation was confirmed using the following controls: tubulin (cytoplasmic),
Ezh2 (nuclear), and lamin B (nuclear). NP, nuclear pellet. E, knockdown (KD) of Ezh2 results in decreased levels of phospho-Ezh2. HeLa cells were infected with
lentiviruses expressing either control shRNA or Ezh2 shRNA. Top panel, quantitative RT-PCR confirming Ezh2 knockdown. Bottom panel, lysates were subjected
to Western blot analysis using the indicated antibodies. Error bars indicate S.D.
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cyclin-dependent kinase, CDK1 specifically associates with
cyclin B, whose level peaks during mitosis. Given that knock-
down of Ezh2 results in the accumulation of cells in G2/M-
phase (supplemental Fig. S1C), CDK1 was an attractive candi-
date for mediating Ezh2 phosphorylation at Thr-345 and
Thr-487.
To explore this possibility, a cold in vitro kinase assay was
performed using purifiedGST-tagged Ezh2 andCDK1-cyclin B
followed by Western blot analysis using the phospho-Ezh2
antibodies described above. As shown in Fig. 3A, phosphory-
lated Ezh2 is detected only when both GST-Ezh2 and CDK1-
cyclin B are present in the reaction. To gain further support that
CDK1 is responsible for Thr-345 and Thr-487 phosphoryla-
tion, we used a potent CDK inhibitor, roscovitine. To this end,
HEK293T cells expressing FLAG-tagged Ezh2 were treated in
the presence or absence of roscovitine. Following FLAG immu-
noprecipitation, the phosphorylation status of Ezh2 was ana-
lyzed by Western blotting. Results shown in Fig. 3B demon-
strate that phosphorylation of both Thr-345 and Thr-487 is
greatly inhibited by the presence of roscovitine, indicating that
CDKs (including CDK1) contribute to Ezh2 phosphorylation at
both sites. Similar analysis also demonstrates that roscovitine
treatment resulted in diminished endogenous phospho-Ezh2
levels in HeLa cells (Fig. 3C). Because roscovitine also inhibits
CDK2 and CDK5 (24), we therefore treated HeLa cells with a
CDK1-specific inhibitor, CGP74514A, for various times.West-
ern blot analysis shown in Fig. 3D demonstrates a decrease in
endogenous phospho-Ezh2 when CDK1 is specifically inhib-
ited, indicating that CDK1 contributes to Ezh2 phosphoryla-
tion at Thr-345 and Thr-487.
We then asked whether phospho-Ezh2 is enriched during
mitosis, which would be expected if Ezh2 was a true CDK1
substrate. To address this question, HeLa cells were arrested at
S-phase and M-phase by double thymidine block and thymi-
dine-nocodazole block, respectively. Western blot analysis
using antibodies for the cell cycle markers cyclin B1 (M-phase)
and SLBP (S-phase) confirmed that the cells were properly
arrested (Fig. 3E). Importantly, an enrichment of phospho-
Ezh2 in the M-phase arrested cells was observed when com-
pared with S-phase arrested cells. Thus, the above data collec-
tively demonstrate that Ezh2 is a CDK1 substrate.
Thr-345 and Thr-487 Are Not Important for Global Levels of
H3K27 Trimethylation—Phosphorylation of Ser-21 was previ-
ously reported to inhibit histone methyltransferase (HMT)
activity (21). Thus, it is logical to ask whether phosphorylation
of Thr-345 and Thr-487 has an effect on Ezh2 activity. There
are two possible ways inwhichThr-345 andThr-487may affect
the HMT activity of Ezh2. 1) They may be crucial residues that
affect the intrinsic enzymatic activity or 2) they may indirectly
affect enzymatic activity through disruption of the Ezh2 inter-
action partners, Suz12 and Eed. It should be noted that these
two possibilities are not mutually exclusive.
To address this question, we first asked whether mutation of
Thr-345 and Thr-487 to alanines affected the ability of Ezh2 to
interact with Suz12. NIH3T3 cells stably expressing the empty
vector (control), FLAG-tagged Ezh2 (WT), or T345A/T487A
(Mut-A) were generated by lentiviral infection. Immunopre-
cipitation using FLAG antibodies followed by Western blot
analysis using Suz12 antibodies demonstrates that both WT
and Mut-A bound to relatively similar amounts of Suz12 (sup-
plemental Fig. S2A). Thus, Thr-345 and Thr-487 do not appear
to be important to maintaining the integrity of the PRC2
complex.
To assess the contributions of Thr-345 and Thr-487 to Ezh2
HMT activity, a dominant negative approach was used. Given
that the phosphorylation-deficient mutant Ezh2 is capable of
interacting with Suz12, it is expected that overexpression of a
mutant Ezh2 would compete with wild-type Ezh2 for interac-
tion with Suz12 and Eed. If Thr-345 and Thr-487 are important
residues for Ezh2 HMT activity, we would expect a global
decrease of trimethylated H3K27. Using this strategy, FLAG-
tagged wild-type Ezh2, T345A, or T487A were expressed in
U2OS cells and were co-immunostained using antibodies
against FLAG and H3K27me3. Results shown in supplemental
Fig. S2B demonstrate that cells expressing wild-type or mutant
Ezh2 have similar H3K27me3 levels, suggesting that mutations
on these residues do not significantly alter the Ezh2HMTactiv-
ity. Consistent with this notion, Western blot analysis of his-
tones from HeLa cells stably expressing wild-type Ezh2,
FIGURE 3. CDK1 mediates Ezh2 phosphorylation at Thr-345 and Thr-487.
A, CDK1 phosphorylates Ezh2 at Thr-345 and Thr-487 (pT487) in vitro. Recom-
binant GST-tagged Ezh2 was subjected to a cold kinase assay using CDK1-
cyclin B kinase followed by Western blot analysis using phospho-Ezh2
antibodies specific for Thr(P)-345 (-pT345) and Thr(P)-487 (-pT487), respec-
tively. B, phosphorylation of Ezh2 by CDKs can be inhibited by roscovitine
(Ros). HEK293T cells were transfected with empty vector (Ctrl) or FLAG-tagged
Ezh2 (F-Ezh2). 24 h after transfection, cells were treated with 50 M roscovitine
for 24 h to inhibit CDKs. Following FLAG immunoprecipitation, bound pro-
teins were subjected to Western blot analysis using the indicated antibodies.
C, inhibition of CDKs results in loss of endogenous phospho-Ezh2. HeLa cells
were treated with 50 M roscovitine for the indicated times (hr Ros). Lysates
were analyzed by Western blot analysis using the indicated antibodies.
DMSO, dimethyl sulfoxide. D, specific inhibition of CDK1 results in loss of
endogenous phospho-Ezh2. HeLa cells were treated with 2 M CGP74514A
(CGP) to specifically inhibit CDK1. Lysates were analyzed by Western blot anal-
ysis using the indicated antibodies. E, phospho-Ezh2 is enriched in cells
arrested at mitosis. HeLa cells were arrested at S-phase (S) and M-phase (M) by
double thymidine block and thymidine-nocodazole block, respectively.
Extracts were analyzed by Western blot using the indicated antibodies. SLBP,
S-phase control; cyclin B1, M-phase control; tubulin, loading control.
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T345A/T487A (Mut-A), or T345E/T487E (Mut-E) demon-
strates that global levels of H3K27me3 are not significantly
altered (supplemental Fig. S2C).
Phosphorylation of Ezh2 Is Important forUbiquitin-mediated
Degradation—Given that both mRNA and protein levels of
Ezh2 accumulate at the G1/S-phase transition (12), we hypoth-
esized that phosphorylation of Ezh2 duringmitosis could func-
tion as a signal for degradation. To examine this possibility, we
compared the half-lives of Thr(P)-345, Thr(P)-487, and total
Ezh2. To this end, we transfected FLAG-tagged wild-type Ezh2
into HEK293T cells and treated cells with the protein synthesis
inhibitor, cycloheximide, for different times. Western blot
analysis using the FLAG antibody allowed for detection of total
exogenous Ezh2, which exhibited a half-life of 2 h (Fig. 4A),
similar to a previous study (25). In contrast, Thr(P)-345 and
Thr(P)-487 Ezh2 proteins exhibited a significantly shorter half-
life when compared with the total Ezh2 (Fig. 4A), although the
two phosphorylated forms have similar half-lives (1 h).
The shorter half-life of phospho-Ezh2may be due to reduced
protein stability or the actions of protein phosphatases. To
assess the first possibility, we examined the protein levels of
wild-type Ezh2 andT345A/T487A (Mut-A) aftermitosis. HeLa
cells stably expressing wild-type Ezh2 or Mut-A were mitoti-
cally arrested and released for various times.Western blot anal-
ysis demonstrates that wild-type Ezh2 is degradedmore rapidly
when compared with Mut-A after mitosis (Fig. 4B), suggesting
that the shorter half-life of phospho-Ezh2 is due to reduced
protein stability.
Because Thr(P)-345 and Thr(P)-487 appear to be less stable
than total Ezh2, we investigated the possibility that phospho-
Ezh2 is targeted for ubiquitination and degradation. To this
end, phospho-Ezh2 and total Ezh2 were immunoprecipitated
from HeLa cells with rabbit IgG as a negative control. Western
blot analysis of bound proteins was performed using antibodies
against Thr(P)-345, Thr(P)-487, total Ezh2, and ubiquitin.
Results shown in Fig. 4C demonstrate that a ladder of bands
reminiscent of polyubiquitinated proteins was observed when
either Thr(P)-345 or Thr-487 is immunoprecipitated. This
result supports the notion that phospho-Ezh2 may serve as a
signal for ubiquitin-mediated degradation.
To further validate that Thr(P)-345 and Thr(P)-487 are
important for degradation of Ezh2, in vivoubiquitination assays
were performed to assess whether mutation of these residues
could affect the ubiquitination status of Ezh2. We first com-
pared the ubiquitination status of wild-type with T345A/
T487A (Mut-A) and T345E/T487E (Mut-E) mutants Ezh2 in
asynchronous cells, which revealed no significant difference
(supplemental Fig. S3A). Given that Ezh2 phosphorylation is
enriched during mitosis (Fig. 3D) and that mitotic cells only
account for 10–20% of the total cell population, the lack of
difference betweenwild-type andmutantsmay simply be due to
the low levels of phospho-Ezh2 in asynchronous cells. To cir-
cumvent this issue, we performed the in vivo ubiquitination
assay using HeLa cells stably expressing Ezh2. After transfec-
tion of HA-tagged ubiquitin, cells were arrested at mitosis by
thymidine-nocodazole block. Prior to harvesting, the cells were
treated with or without the proteasome inhibitor, MG132.
Although ubiquitinated Ezh2 was not detected in the untreated
cells, likely due to its quick degradation, wild-type Ezh2 was
clearly ubiquitinated when mitotic cells were treated with
MG132 (Fig. 4D, right panel, lane 2). Importantly, mutation of
both Thr-345 and Thr-487 to either an alanine (Mut-A) or a
glutamate (Mut-E) dramatically reduced ubiquitination of
Ezh2 (Fig. 4D, right panel, compare lane 2 with lanes 3 and 4).
Interestingly, Mut-E was modestly ubiquitinated, suggesting
that this mutation can partially act as a phospho-mimetic. Col-
lectively, the above data demonstrate that phospho-Ezh2 is
degraded via the ubiquitin pathway.
FIGURE 4. Phosphorylated Ezh2 is ubiquitinated and degraded via the
proteasome pathway. A, phospho-Ezh2 exhibits a shorter half-life when
compared with total Ezh2. Asynchronous HEK293T cells were transfected
with FLAG-tagged Ezh2 and treated with 100 g/ml cycloheximide (CHX) for
the indicated times. Western blot analysis was performed using the indicated
antibodies (top panel). Western blot signals were quantified using ImageJ
(bottom panel). -pT345, Thr(P)-345 antibody; -pT487, Thr(P)-487 antibody.
B, mutant Ezh2 degrades more slowly after mitosis. HeLa cells stably express-
ing FLAG-tagged wild-type Ezh2 (WT) or T345A/T487A (Mut-A) were synchro-
nized at mitosis by thymidine-nocodazole block and then released into the
cell cycle for the times indicated. Protein levels of Ezh2 were detected by
FLAG Western blot (top panel). Cyclin B1 is a marker for mitosis, and tubulin
was used as a loading control. Western blot signals were quantified using
ImageJ (bottom panel). C, phospho-Ezh2 is ubiquitinated. Phospho-Ezh2 was
immunoprecipitated from HeLa extracts using antibodies against Thr(P)-345
and Thr(P)-487. Total Ezh2 was immunoprecipitated using Ezh2 antibodies.
Western blot analysis of bound proteins was performed using the antibodies
indicated. D, ubiquitination status of Ezh2 in mitotic cells. HeLa cells stably
expressing empty vector (Ctrl), FLAG-tagged wild-type Ezh2 (WT), T345A/
T487A (Mut-A), and T345E/T487E (Mut-E) were generated by lentiviral infec-
tion and transfected with HA-tagged ubiquitin. Cells were synchronized and
arrested at mitosis by thymidine-nocodazole block. 4 h prior to harvesting,
cells were treated with or without 25 M MG132. Lysates were prepared
under denaturing conditions and subjected to immunoprecipitation (IP)
using FLAG antibodies. Bound proteins were analyzed by Western blot using
the indicated antibodies.
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Ezh2 Thr-345 and Thr-487 Are Important for Cell
Proliferation—The fact that Ezh2 is important for cell prolifer-
ation (supplemental Fig. S1B) (12) coupledwith the observation
that phosphorylation of Ezh2 is subject to cell cycle regulation
prompted us to ask whether Thr-345 and Thr-487 of Ezh2 are
important for cell proliferation. To this end, prostate cancer
cells (PC3) and HeLa cells were infected with lentiviruses
expressing the empty vector (control), FLAG-tagged wild-type
Ezh2 (WT), or T345A/T487A mutant Ezh2 (Mut-A). Western
blot analysis demonstrates that wild-type and mutant Ezh2
were expressed at relatively similar levels (Fig. 5, A and B). Cell
proliferation was monitored by absorbance using the MTS
assay, and the number of cells was calculated using a standard
curve. Consistent with a previous study (12), overexpression of
Ezh2 in bothPC3 andHeLa cells results in a proliferative advan-
tage when compared with the control (Fig. 5,C andD, compare
dashed line with solid line). Interestingly, both cell lines
expressing Mut-A proliferated significantly more slowly when
compared with wild type (Fig. 5, C and D, compare dotted line
with dashed line). These results support the importance of Thr-
345 and Thr-487 of Ezh2 in regulating cell proliferation.
DISCUSSION
In this study, we present evidence demonstrating that Ezh2 is
subject to phosphorylation at two highly conserved residues,
Thr-345 and Thr-487, which are bona fide CDK1 substrates.
Consistent with the cell cycle-regulated activity of CDK1, Ezh2
phosphorylation is enriched during mitosis. Phospho-Ezh2
exhibits reduced stability due to its ubiquitination and degra-
dation by the proteasome. In addition, cells expressing Ezh2
where both threonines aremutatedmanifest a proliferative dis-
advantage in at least two cell types. Thus, our studies establish a
role for Thr-345 and Thr-487 in regulating Ezh2 stability, a
novel consequence of CDK1-mediated phosphorylation.
The significance of CDK1-mediated regulation of Ezh2
stems from the necessity for a cell to transmit its epigenetic
marks to daughter cells during replication. The mechanisms
underlying cellular memory are poorly understood, although it
is evident that Ezh2 (as well as other Polycomb group proteins)
plays a significant role in this process. Interestingly, the PRC2
complex can bind to H3K27me3 and was observed to co-local-
ize with this mark during G1 as well as sites of ongoing DNA
replication (26), which led to the proposal that PRC2 binds to
established H3K27me3 during DNA replication and transmits
the mark to the newly synthesized histones incorporated into
the daughter strand. Given the amount of epigenetic informa-
tion that must be transmitted to the daughter strands, one
might expect to observe up-regulation of Ezh2 prior to DNA
replication. Consistent with this notion, the pRB-E2F pathway
up-regulates Ezh2 at bothmRNA and protein levels at theG1 to
S transition (12).
After the cell has successfully replicated its DNA and trans-
mitted its epigenetic marks, excess Ezh2 accumulated during
the G1 to S transition might need to be purged to restore the
normal level. Thus, mitotic phosphorylation of Ezh2 and sub-
sequent degradation by the ubiquitination pathwaymight serve
such a purpose (Fig. 6). Because Ezh2 binds and represses the
CDKN2A tumor suppressor locus (16–18), degradation of
excess Ezh2 after mitosis may be important to keep cell prolif-
eration in check.
At the time this work was nearing completion, three studies
concerning CDK1-mediated phosphorylation at Thr-345 and
Thr-487 were published (27–29). Chen et al. (27) provided evi-
dence demonstrating that phosphorylation of Thr-350 (Thr-
345 in mouse Ezh2) is important for the recruitment of Ezh2
and maintenance of H3K27 trimethylation at PRC2 target loci
includingHOXA9 andDAB2IP. This could be explained by the
observation that the phospho-mimetic mutant T345E exhibits
enhanced binding to the lncRNAs HOTAIR and XIST, which
are known to recruit Ezh2 to target loci (28). On the other hand,
Wei et al. (29) reported that phosphorylation at Thr-492 (Thr-
487 in mouse Ezh2) disrupts Ezh2 binding with other PRC2
components, Suz12 and Eed, thereby attenuating Ezh2methyl-
transferase activity.
Collectively, these studies show that Thr-345 and Thr-487
phosphorylation can function distinctively. Expression of
human T350A, but not T492A, resulted in slower cell prolifer-
ation (27, 29), suggesting that the proliferative disadvantage we
observed in cells expressing mouse T345A/T487A was due to
loss of phosphorylation of Thr-345, but not Thr-487. Addition-
ally, cancer cell migration and invasion required Thr-350 (27),
but expression of the phospho-deficient mutant T492A
enhanced these two processes (29). Thus, Thr(P)-350 and
Thr(P)-492 appear to play opposing roles in cancer cell migra-
tion and invasion. It will be interesting to determine which of
these modifications dominates given that these two phosphor-
FIGURE 5. Thr-345 and Thr-487 of Ezh2 are important for cell prolifera-
tion. Western blot analysis demonstrates that wild type and T345A/T487A
mutant are expressed at similar levels. A and B, PC3 (A) and HeLa (B) cells were
infected with lentiviruses overexpressing empty vector (Ctrl), wild-type Ezh2
(WT), or T345A/T487A (Mut-A). Exogenous Ezh2 was detected using FLAG
antibodies, whereas tubulin served as a loading control. C and D, PC3 (C) and
HeLa (D) cells expressing T345A/T487A proliferate more slowly when com-
pared with wild type. Approximately 5000 cells were seeded in triplicate in a
96-well plate, and cell proliferation was monitored by absorbance using the
MTS assay at the indicated times. The measured absorbance was converted to
the number of cells using a standard curve. For each cell line, the number of
cells at day 0 was set to 1. Error bars in panels C and D indicate S.D.
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ylation sites can exist simultaneously within mouse Ezh2 (Fig.
4C).
A role for Thr-350 phosphorylation in regulating Ezh2 pro-
tein stability was also investigated by Chen et al. (27), but the
authors concluded that it had no effect. However, the basis of
their conclusion stemmed from an experiment where the half-
lives of wild-type andT350AEzh2were compared and found to
be similar. We also initially compared the half-lives of wild-
type,Mut-A, andMut-E Ezh2 and came to the same conclusion
(supplemental Fig. S3B). However, phosphorylation of Ezh2
occurs during mitosis (Fig. 3E), and it is estimated that in asyn-
chronous cells, only 1% of Ezh2 is phosphorylated at Thr-345
(28). For this reason, we compared the half-life of phospho-
Ezh2 with total Ezh2 and concluded that phospho-Ezh2 has a
shorter half-life when compared with the total Ezh2 (Fig. 4A).
We further substantiated our conclusion by demonstrating that
Mut-A is degraded less rapidly after mitosis (Fig. 4B) and that
ubiquitination of Ezh2 is impaired in the mutants Mut-A and
Mut-E (Fig. 4, C and D).
At first glance, it may seem contradictory that phosphoryla-
tion of Thr-345 leads to Ezh2 instability given that this modifi-
cation is also important for lncRNA binding to facilitate
recruitment of Ezh2 to target promoters (28). However, it
should be noted that these two consequences are not necessar-
ily mutually exclusive. Because Thr(P)-345 constitutes a small
fraction of total Ezh2, Kaneko et al. (28) suggest that this form
of Ezh2 may be important for the initial establishment of the
H3K27me3 mark. This mark can later be propagated by other
PRC2 complexes regardless of their Ezh2 phosphorylation sta-
tus especially because PRC2 can bind to H3K27me3 (26). Thus,
Ezh2 Thr(P)-345 may be degraded after the recruitment of
PRC2 to their targets by lncRNAs and the initial establishment
FIGURE 6. A model depicting the role of Ezh2 phosphorylation during mitosis. During mitosis when CDK1 kinase activity is high, Ezh2 is phosphorylated
(circled P) at Thr-345 and Thr-487 (Box 1). Phosphorylation of Thr-345 facilitates Ezh2 interaction with lncRNAs including HOTAIR (Box 2), which recruits PRC2
(other components not shown) to Polycomb target genes. Initial H3K27me3 marks are placed on the newly incorporated histones of the daughter strand by
PRC2 containing phospho-Ezh2 (Box 3). Phosphorylated Ezh2 is then ubiquitinated (Ub) and degraded via the proteasome, whereas additional PRC2 complexes
(regardless of their Ezh2 phosphorylation status) bind to the initial trimethyl H3K27 mark and propagate the mark (Box 4).
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of H3K27me3 marks (Fig. 6). This model is particularly attrac-
tive because initial recruitment of Ezh2 may be more specific
due to the use of lncRNAs.Given that we presently do not know
the kinetics of Ezh2 recruitment, we cannot confirm this
possibility.
In summary, the findings described in this study coupled
with the studies by other groups demonstrate an important role
forCDK1-mediated phosphorylation of Ezh2. Like Ezh2, CDK1
activity is positively associated with cell proliferation and can-
cer (30) and has emerged as a central player in controlling ES
cell self-renewal and lineage specification (31). Thus, this
mechanism of Ezh2 regulation may provide valuable insight
into the development of therapeutic drugs aswell asmethods in
regenerative medicine.
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